Samsung Biologics Co.,Ltd. (KRX: 207940)

Market Cap	68.83T
Revenue (ttm)	4.36T
Net Income (ttm)	1.05T
Shares Out	71.17M
EPS (ttm)	14,787.79
PE Ratio	65.39
Forward PE	62.85
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,866
Open	983,000
Previous Close	971,000
Day's Range	970,000 - 991,000
52-Week Range	698,000 - 1,113
Beta	0.39
Analysts	n/a
Price Target	n/a
Earnings Date	Jan 24, 2025

About Samsung Biologics Co.,Ltd.

Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization. Its development services include discovery, cell line development, process development, and clinical manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality ass...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 4,744
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 207940

Financial Performance

In 2023, Samsung Biologics Co.,Ltd.'s revenue was 3.69 trillion, an increase of 23.10% compared to the previous year's 3.00 trillion. Earnings were 857.69 billion, an increase of 7.47%.